ClinicalTrials.gg
RecruitingNCT06021808Updated Jun 13, 2024

LAA Clipping Versus NOACs to Prevent Stroke in Non-paroxysmal Atrial Fibrillation.

An interventional study of Thoracoscopic LAA clipping and Novel oral anticoagulant in Non-paroxysmal Atrial Fibrillation, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-13.

Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Stroke by China National Center for Cardiovascular Diseases — 11 open to participants now, 11 under way, none of them phase 3. Stroke · China National Center for Cardiovascular Diseases.

Started
2024
with 2 others
No phase
5 of 12
4 open now
Primary completion
2028-04
later than 6 of 10 live
Registered
5th of 12
by date

Among the 12 studies in Stroke by China National Center for Cardiovascular Diseases, this one is one of 3 that started in 2024, is one of 5 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 5th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

11 of the 12 studies in Stroke by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Stroke by China National Center for Cardiovascular Diseases, or all of them as a file.
02

Study summary

This trial is designed to examine the hypothesis that thoracoscopic LAA clipping is superior to NOACs for stroke, systemic embolism, all-cause mortality, major bleeding events and clinically relevant nonmajor bleeding events in AF patients at high risk of embolism (CHA2DS2-VASc ≥2 in men and ≥3 in women) that are not undergoing ablation.

Read the detailed description

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia disease, and the incidence of AF increases markedly with age and approximately doubles with each decade. According to the previous study, the incidence of stroke were five times in patients with AF than those in the general population. Systemic oral anticoagulant is a well-established, guideline-recommended therapy for the prevention of ischemic stroke in patients with nonvalvular AF at high risk of embolism (CHA2DS2-VASc scores ≥2 in men and ≥3 in women), and the guidelines recommend that the novel oral anticoagulants (NOACs) be preferred (Class I, Level of evidence A). However, a significant proportion of patients with nonvalvular AF have difficulties in long-term oral anticoagulant therapy, due to medication adherence and contraindications to oral anticoagulants. Also, several randomized controlled trials indicated that bleeding risk remained high with novel oral anticoagulants. Therefore, it is essential to explore alternative treatment strategies for stroke prevention in patients with nonvalvular AF.

It has been reported that the left atrial appendage (LAA) is suspected as a vital source of cerebral emboli and may lead to ischemic stroke, removal or closure of the LAA may be an alternative to oral anticoagulants. Various surgical or interventional approaches have been developed to close or occlude LAA to prevent stroke in AF patients, such as percutaneous LAA occlusion, suture ligation, and surgical excision. However, these techniques suffer from incomplete LAA closure or the presence of residual blood flow, which can lead to thrombosis and stroke. Thoracoscopic LAA clip, on the other hand, cloud block blood flow between the LAA and the left atrium (LA), achieving isolation of LAA and preventing thrombi and strokes. A previous study has demonstrated a high 95% success rate of LAA clipping without operation-related complications, and freedom from stroke was 99.1% at a median follow-up of 20 months. Therefore, LAA clipping is an effective and durable method in stroke prevention. However, currently high-quality RCTs are lacking to support the superiority of LAA clipping compared with NOACs in terms of stroke prevention and safety. In this trial, the investigators designed a multicenter prospective RCT to compare the efficacy and safety of thoracoscopic LAA clipping and NOACs in patients with non-paroxysmal AF.

03

Conditions studied

  • Non-paroxysmal Atrial Fibrillation

Keywords

  • left atrial appendage clipping
  • Stroke
  • Oral anticoagulation
  • Atrial Fibrillation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Persistent or long-standing persistent AF documented by medical history or direct .
  • CHA2DS2-VASc ≥2 in men and ≥3 in women.
  • Agree to perform thoracoscopic LAA occlusion procedure.

Exclusion criteria

Exclusion Criteria:

  • With electrical cardioversion or ablation intent.
  • Other heart diseases with surgical indications.
  • Ischemic stroke and other cardiac embolic events within 30 days.
  • Major clinical bleeding event within 30 days.
  • to anticoagulation.
  • Intracardiac thrombus.
  • (LVEF) \< 30%.
  • Active systemic infection or infective endocarditis or pericarditis
  • Severe liver disease (acute clinical hepatitis, chronic active hepatitis, cirrhosis) or (ALT)/ aspartate transaminase (AST) greater than 3 times the value.
  • Severe renal insufficiency ( ≤ 30mL/min).
  • Other diseases requiring oral anticoagulants.
  • Active aortic plaque.
  • Acute coronary syndrome within 3 months.
  • Symptomatic carotid artery stenosis.
  • Patients requiring dual antiplatelet drug therapy.
  • Previous cardiac and left lung surgery.
  • Severe left pleural and pericardial adhesions.
  • Pregnant or breastfeeding patients.
  • Metal allergies.
  • Terminal illness with a of less than 2 years.
  • Participation in other clinical studies at the time of enrollment.
  • Refuse to participate in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
290 participants (estimated)

Study arms

  • Experimental
    LAA clipping group

    In this arm, participants are performed thoracoscopic LAA clipping.

    Procedure: Thoracoscopic LAA clipping

  • Active comparator
    NOACs group

    Patients randomized to NOAC therapy will begin long-term oral administration of NOACs immediately after enrollment.

    Drug: Novel oral anticoagulant

Interventions

  • ProcedureThoracoscopic LAA clipping

    The surgeons measured the length of the base of the LAA, an appropriately sized LAA clip is then inserted with the aid of a thoracoscope and placed parallel to the base of the LAA.

  • DrugDirect Oral AnticoagulantStudies of Direct Oral AnticoagulantDirect Oral Anticoagulant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    For patients with creatinine clearance ≥50 ml/min, oral rivaroxaban 20 mg daily was administered, whereas for patients with creatinine clearance between 30-49 ml/min, oral rivaroxaban 15 mg daily was administered.

06

What researchers measure

Primary outcomes

  1. Rate of composite endpoint

    Stroke, systemic embolism, all-cause mortality, major bleeding event, and clinically relevant non-major bleeding event.

    Time frame: At 24-month after intervention

Secondary outcomes

  1. Rate of stroke

    Acute episodes of focal or global neurological dysfunction due to cerebral, spinal cord or retinal vascular injury from haemorrhage or infarction. Symptoms or signs must have lasted ≥ 24 hours, or symptoms/signs may have lasted less than 24 hours if demonstrated by CT, MRI, or autopsy.

    Time frame: At 24-month after intervention

  2. Rate of systemic embolism

    Confirmed by imaging or angiography

    Time frame: At 24-month after intervention

  3. Rate of all-cause mortality

    Deaths from all causes

    Time frame: At 24-month after intervention

  4. Rate of major bleeding event

    1. fatal haemorrhage, and/or 2. Symptomatic haemorrhage in a critical area or organ, such as intracranial, intravertebral, intraocular, retroperitoneal, intra-articular or intrapericardial, or intramuscular haemorrhage leading to osteofascial compartment syndrome, and/or 3. haemorrhage that results in a fall in haemoglobin level of 2.0 g/dL or more, or that results in the importation of two or more units of whole blood or red blood cells.

    Time frame: At 24-month after intervention

  5. Rate of clinically relevant non-major bleeding event

    Bleeding events that do not meet the criteria for an ISTH major bleeding event but requires hospitalisation or a change in antithrombotic treatment strategy or requires invasive management.

    Time frame: At 24-month after intervention

  6. Rate of surgery-related complications

    Incidence of in-hospital death, in-hospital stroke, intermediate small-incision open thoracotomy or median open thoracotomy, and postoperative re-intervention due to hemorrhage, pneumothorax, and pyothorax.

    Time frame: At 24-month after intervention

  7. Rate of minor bleeding events

    Bleeding events that do not meet the ISTH criteria for a major bleeding event, do not meet the criteria for a clinically relevant non-major bleeding event, and do not require the subject to seek additional assistance from medical care.

    Time frame: At 24-month after intervention

07

Study locations

1 of 1 sites recruiting
  • China National Center for Cardiovascular Diseases
    Beijing, Beijing 100037, China
    Recruiting
    • Zhe Zheng, M.D., Ph.D. · Contactzhengzhe@fuwai.com · 8610-8839-6051
    • Chunyu Yu, MD · Contactyuchunyu@fuwai.com
    • Zhe Zheng, M.D., Ph.D. · Principal investigator
    • Chunyu Yu, MD · Sub investigator
    • Haojie Li, MD · Sub investigator
    • Chuxiang Lei, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2028, 48 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 48 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2023
First posted
Sep 1, 2023
StartActual
Apr 2, 2024
Primary completionEst.
Apr 2028
CompletionEst.
May 2028
Last update
Jun 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06021808
Responsible party
Sponsor
First posted
Sep 1, 2023
Start date
Apr 2, 2024
Primary completion
Apr 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Jun 13, 2024

Study contacts

Zhe Zheng, MD,PhD
Contact
zhengzhe@fuwai.com
+86-010-88396051
Chunyu Yu, MD
Contact
yuchunyu@fuwai.com
Zhe Zheng, MD,PhD
study chair · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion